For: | Wood PR, Manning E, Baker JF, England B, Davis L, Cannon GW, Mikuls TR, Caplan L. Blood glucose changes surrounding initiation of tumor-necrosis factor inhibitors and conventional disease-modifying anti-rheumatic drugs in veterans with rheumatoid arthritis. World J Diabetes 2018; 9(2): 53-58 [PMID: 29531640 DOI: 10.4239/wjd.v9.i2.53] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v9/i2/53.htm |
Number | Citing Articles |
1 |
Chrong-Reen Wang, Hung-Wen Tsai. Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. World Journal of Diabetes 2021; 12(3): 238-260 doi: 10.4239/wjd.v12.i3.238
|
2 |
Enver Ciftel, Filiz Mercantepe, Tolga Mercantepe, Kerimali Akyildiz, Adnan Yilmaz, Serpil Ciftel. Comparative Analysis of Epigallocatechin-3-Gallate and TNF-Alpha Inhibitors in Mitigating Cisplatin-Induced Pancreatic Damage Through Oxidative Stress and Apoptosis Pathways. Biological Trace Element Research 2024; 202(11): 5190 doi: 10.1007/s12011-024-04239-9
|
3 |
Claudia Di Muzio, Paola Cipriani, Piero Ruscitti. Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association. BioDrugs 2022; 36(6): 673 doi: 10.1007/s40259-022-00561-7
|
4 |
L. V. Kondratieva, T. V. Popkova, E. L. Nasonov. Influence of biologics on carbohydrate metabolism and risk of diabetes. Rheumatology Science and Practice 2019; 57(2): 222 doi: 10.14412/1995-4484-2019-222-228
|
5 |
Jesper Johannesen, Flemming Pociot. Textbook of Diabetes. 2024; : 1123 doi: 10.1002/9781119697473.ch76
|